Capital World Investors Autolus Therapeutics PLC Transaction History

Capital World Investors

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$2.04 - $4.68 $888,581 - $2.04 Million	-435,579 Reduced 41.07%	625,000 $1.77 Million
Q1 2022 May 16, 2022	SELL	$3.52 - $5.46 $6.67 Million - $10.3 Million	-1,895,227 Reduced 64.12%	1,060,579 $4.42 Million
Q1 2020 May 15, 2020	BUY	$4.2 - $13.0 $3.19 Million - $9.88 Million	760,000 Added 34.61%	2,955,806 $17.7 Million
Q4 2019 Feb 18, 2020	BUY	$11.13 - $16.28 $5.49 Million - $8.03 Million	492,976 Added 28.95%	2,195,806 $29 Million
Q3 2019 Nov 14, 2019	BUY	$9.79 - $16.72 $283,332 - $483,893	28,941 Added 1.73%	1,702,830 $21.1 Million
Q2 2019 Aug 14, 2019	BUY	$15.1 - $31.25 $16 Million - $33.2 Million	1,062,777 Added 173.91%	1,673,889 $27 Million
Q3 2018 Nov 14, 2018	SELL	$20.86 - $33.33 $10.2 Million - $16.3 Million	-488,888 Reduced 44.44%	611,112 $18.4 Million
Q2 2018 Aug 14, 2018	BUY	$25.0 - $27.75 $27.5 Million - $30.5 Million	1,100,000 New	1,100,000 $29.5 Million

114

160M

2.8K

89.9K

Ticker AUTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 90,909,800
Market Cap $185M
Description
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...

Get notified when there are updates to the investment portfolio of Capital World Investors, based on Form 13F filings with the SEC.

Stay updated on Capital World Investors with notifications on news.